#USA #Fort Lauderdale #Cancer Treatment #Kefunova #SKNV

A New Era in Dermatology: The Launch of Kefunova™

In a significant milestone for dermatology, SKNV has officially launched its latest product, Kefunova Cream, designed specifically for patients suffering from actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). This new prescription-only medication combines two well-regarded active ingredients: Fluorouracil, recognized for its effectiveness as a topical chemotherapy agent, and Calcipotriene, a vitamin D analog that enhances skin health.

Meeting a Growing Need

As dermatologists frequently encounter cases of AK and sBCC, the demand for effective treatment options has surged. SKNV’s CEO, Spencer Malkin, emphasizes that the creation of Kefunova was a direct response to this need within the clinical community. “Kefunova is exactly what dermatology providers have been asking for—a trusted, high-quality option to target actinic keratosis and superficial basal cell carcinoma,” he declared, highlighting the importance of integrating such a product into existing treatment plans.

The cream exhibits a synergistic approach to treatment, capitalizing on the strengths of its two active ingredients. Fluorouracil works by inhibiting abnormal cell growth, while Calcipotriene stimulates the skin's healing processes. Together, they provide a comprehensive strategy for lesion clearance through which patients can experience accelerated cell turnover and immune activation.

Quality Assurance and Accessibility

Manufactured at SKNV's FDA-Registered 503B Outsourcing Facility, Kefunova Cream is produced under strict cGMP standards, assuring healthcare providers and patients of its quality and reliability. The cream is not only straightforward to use but is also available for both in-office dispensing and electronic prescribing through electronic medical record (EMR) systems. This flexibility allows healthcare practitioners to adapt their treatment plans according to their patients’ needs while responding to the escalating prevalence of actinic keratosis and superficial basal cell carcinoma in the population.

Empowering Both Providers and Patients

Kefunova Cream is aimed at improving patient access to care, offering a viable option for those navigating the often uncertain path of dermatological conditions. With affordability and accessibility in mind, SKNV positions its new product as a beacon of hope for patients across the nation, bringing them closer to effective management of their skin conditions.

Providers can explore more about Kefunova or place orders by visiting www.sknv.com/kefunova. This launch marks a notable advancement in dermatological treatment, empowering practitioners with another tool to provide effective patient care.

About SKNV

With a mission to revolutionize dermatologic care, SKNV focuses on creating high-quality topical medications framed by patient accessibility. The company is dedicated to easing the burden on dermatology practices by alleviating common pharmacy hurdles like prior authorizations. SKNV facilitates better patient experiences through efficient medication access whether through in-office dispensing or direct prescriptions. They cater to numerous dermatological conditions, including acne, melasma, rosacea, and alopecia.

Serving over 4,000 providers across the country, SKNV is committed to enhancing patient satisfaction while continuously innovating to set new standards in dermatology. Learn more about their offerings at www.sknv.com.

Conclusion

The introduction of Kefunova Cream by SKNV is expected to make impactful changes in how dermatologists approach the treatment of actinic keratosis and superficial basal cell carcinoma. It aligns patient care with advanced clinical practices, ensuring that providers have the necessary tools to support positive health outcomes.